Canaccord Genuity Morning Coffee on Johnson & Johnson (JNJ): Big Legal Bills To Get Bigger
Tweet Send to a FriendGet Alerts JNJ Hot Sheet
Price: $86.82 -0.45%
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
8 Buy, 9 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade JNJ Now!
Canaccord Genuity Morning Coffee on Johnson & Johnson (NYSE: JNJ): Big legal bills to get bigger.
Last Friday, Johnson & Johnson announced that it set aside an extra $600 million to settle U.S. investigations and lawsuits into abusive marketing practices involving its Risperdal antipsychotic drug and other medications. But the legal bill seems to be growing as Bloomberg News reported that the settlement figure has risen to as much as $2.2 billion, citing two people familiar with the negotiations. If that figure holds, it would be the government’s second largest settlement with a pharmaceutical company, behind a $2.3-billion accord that Pfizer (NYSE: PFE) entered in 2009 to resolve U.S. investigations of improper marketing of its Bextra painkiller. The settlement, which could be announced this week, would include a criminal penalty of as much as $600 million, as well as a misdemeanor plea, according to Bloomberg. The deal would also resolve civil claims that J&J paid kickbacks to Omnicare (NYSE: OCR), a health care services company that dispenses drugs in nursing homes. In 2010, U.S. attorneys joined two whistle-blower law suits alleging J&J made improper payments to Omnicare to get the company to buy more of its schizophrenia drugs Risperdal and Invega and respiratory drug Natrecor, and Omnicare's pharmacists then recommended that doctors prescribe those drugs. J&J claims it gave standard discounts to Omnicare, and that those discounts were not illegal as long as they were properly disclosed. Separately, an experimental treatment for type 2 diabetes developed by J&J demonstrated greater reduction in blood sugar than Merck's (NYSE: MRK) Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Last Friday, Johnson & Johnson announced that it set aside an extra $600 million to settle U.S. investigations and lawsuits into abusive marketing practices involving its Risperdal antipsychotic drug and other medications. But the legal bill seems to be growing as Bloomberg News reported that the settlement figure has risen to as much as $2.2 billion, citing two people familiar with the negotiations. If that figure holds, it would be the government’s second largest settlement with a pharmaceutical company, behind a $2.3-billion accord that Pfizer (NYSE: PFE) entered in 2009 to resolve U.S. investigations of improper marketing of its Bextra painkiller. The settlement, which could be announced this week, would include a criminal penalty of as much as $600 million, as well as a misdemeanor plea, according to Bloomberg. The deal would also resolve civil claims that J&J paid kickbacks to Omnicare (NYSE: OCR), a health care services company that dispenses drugs in nursing homes. In 2010, U.S. attorneys joined two whistle-blower law suits alleging J&J made improper payments to Omnicare to get the company to buy more of its schizophrenia drugs Risperdal and Invega and respiratory drug Natrecor, and Omnicare's pharmacists then recommended that doctors prescribe those drugs. J&J claims it gave standard discounts to Omnicare, and that those discounts were not illegal as long as they were properly disclosed. Separately, an experimental treatment for type 2 diabetes developed by J&J demonstrated greater reduction in blood sugar than Merck's (NYSE: MRK) Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
- Janney Capital Boosts PT on Gap (GPS) Post Q1
Create E-mail Alert Related Categories
Analyst Comments, LitigationComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Risperdal reproached
Daniel Haszard on Jun 12, 2012 11:41 AMMark as Spam | Reply to this comment
A customer victim speaks
Risperdal reproached.
The saga of the so called *atypical antipsychotics* is one of incredible profit.Eli Lilly made $65 BILLION on Zyprexa.Described as *the most successful drug in the history of neuroscience* the drugs at $12 pill are used by states to medicate deinstitutionalized mental patients to keep them out of the $500-$1,200 day hospitals.
There is a whole underclass block of our society,including children in foster care that are the market for these drugs,but have little voice of protest if harmed by them.I am an exception,I got diabetes from Zyprexa as an off-label treatment for PTSD and I am not a mentally challenged victim so I post.
--Daniel Haszard